Skip to main content

Advertisement

SpringerLink
Log in

Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

The aim of the present study was to evaluate inflammatory, oxidative, and nitrosative stress (IO&NS) blood markers as possible predictors of multiple sclerosis (MS) and its clinical forms. This study included 258 MS patients (175 with relapsing-remitting MS (RRMS) and 83 with progressive MS clinical forms) and 249 healthy individuals. Peripheral blood samples were obtained to determine serum levels of albumin, ferritin, C-reactive protein (CRP), total protein, lipid hydroperoxide by tert-butyl hydroperoxide-initiated chemiluminescence (CL-LOOH), carbonyl protein content, advanced oxidation protein products (AOPP), nitric oxide metabolites (NOx), and total radical-trapping antioxidant parameter (TRAP). MS patients showed higher ferritin (p < 0.001) and CL-LOOH (p < 0.001) and lower albumin (p = 0.001), TRAP (p < 0.001), AOPP (p = 0.013), and NOx values (p < 0.001) than controls. Difference was not observed in CRP, total protein, and carbonyl proteins between patients and controls. In the logistic regression age-adjusted, ferritin and CL-LOOH showed positive association with MS and were predictors of MS development (OR: 1.006, 95 % CI: 1.003–1.009, p < 0.001 and OR: 1.029, 95 % CI: 1.007–1.052, p = 0.009, respectively). Albumin, TRAP, AOPP, and NOx were negatively associated with MS (p = 0.019, p = 0.003, p = 0.001, and p = 0.003, respectively). Moreover, other logistic regression age-adjusted showed that MS patients with progressive clinical forms had lower albumin and higher AOPP than those with RRMS (p = 0.037). In conclusion, ferritin, albumin, and biomarkers of IO&NS, such as CL-LOOH, AOPP, TRAP, and NOx were predictors of MS diagnosis, whereas albumin and AOPP were predictors that differentiated RRMS from the progressive clinical forms of MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. LeVine SM, Lynch SG, Ou CN, Wulser MJ, Tam E, Boo N (1999) Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res 821:511–515

  2. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC (2014) Onset of secondary progressive phase and longterm evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85:67–75

  3. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911

    Article  CAS  PubMed  Google Scholar 

  4. Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11:677–682

  5. Oliveira SR, Kallaur AP, Simão AN, Morimoto HK, Lopes J, Panis C, Petenucci DL, da Silva E et al (2012) Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 321:49–53

  6. Haider L (2015) Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. Celular Oxid Med Longev 2015:725.370

    Google Scholar 

  7. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, Sancesario G, Bernardini S et al (2014) Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 3:304–312

  8. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J (2013) Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 4, e61835

  9. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

  10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302

  11. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    Article  CAS  PubMed  Google Scholar 

  12. Brazil IBGE (2011) Brazilian Institute of Geography and Statistics. Characteristics of the Population and Households: Results of the Universe. Available in://http://www.ibge.gov.br/english/estatistica/populacao/censo2010/caracteristicas_da_populacao/default_caracteristicas_da_populacao.shtm. Accessed 16 July, 2013.

  13. Gonzales-Flecha BG, Llesuy S, Boveris A (1991) Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic Biol Med 10:93–100

    Article  Google Scholar 

  14. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524–2532

  15. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simão AN, Cecchini AL et al (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133:89–97

  16. Repetto M, Reides C, Gomez Carretero ML, Costa M, Griemberg G, Llesuy S (1996) Oxidative stress in blood of HIV infected patients. Clin Chim Acta 255:107–117

  17. Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J (2007) Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 14:529–533

  18. Grune T, Merker K, Sandig G, Davies KJ (2003) Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 3:709–718

    Article  Google Scholar 

  19. Lozovoy MA, Simão AN, Oliveira SR, Iryioda TM, Panis C, Cecchini R, Dichi I (2013) Relationship between iron metabolism, oxidative stress, and insulin resistance in patients with systemic lupus erythematosus. Scand J Rheumatol 4:303–310

  20. de Bustos F, Navarro JA, de Andrés C, Molina JA, Jiménez-Jiménez FJ, Ortí-Pareja M, Gasalla T, Tallón-Barranco A et al (1999) Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol 41:44–47

  21. Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L (2003) Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 136:112–118

  22. Guthikonda P, Baker J, Mattson DH (1998) Interferon-beta-1-b (IFN-β) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol 82:133–139

    Article  CAS  PubMed  Google Scholar 

  23. Simão AN, Lozovoy MA, Simão TN, Venturini D, Barbosa DS, Dichi JB, Matsuo T, Cecchini R et al (2011) Immunological and biochemical parameters of patients with metabolic syndrome and the participation of oxidative and nitroactive stress. Braz J Med Biol Res 44:606–728

  24. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274:48–53

    Article  CAS  PubMed  Google Scholar 

  25. van Meeteren ME, Teunissen CE, Dijkstra CD, van Tol EA (2005) Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 59:1347–1361

  26. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV (2010) Serum ferritin: past, present and future. Biochim Biophys Acta 1800:760–769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Strupp M (2010) News on multiple sclerosis: induction of immune tolerance, a biomarker for predicting disease activity, and CSF ferritin levels. J Neurol 257:2114–2116

    Article  PubMed  Google Scholar 

  28. Connor JR, Boeshore KL, Benkovic SA, Menzies SL (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37:461–465

  29. Arosio P, Levi S (2002) Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med 33:457–463

    Article  CAS  PubMed  Google Scholar 

  30. Sitar ME, Aydin S, Cakatay U (2013) Human serum albumin and its relation with oxidative stress. Clin Lab 59:945–949

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Postgraduate Program, Health Sciences Center, University of Londrina, Av. Robert Koch, 60, 86038-440, Londrina, Paraná, Brazil

    Sayonara R. Oliveira & Ana Paula Kallaur

  2. Department of Pathology, Clinical Analysis, and Toxicology, Health Sciences Center, University Hospital, State University of Londrina, Av. Robert Koch 60, Vila Operária, CEP 86038-350, Londrina, Paraná, Brazil

    Edna M. V. Reiche, Marcell Alysson B. Lozovoy, Helena K. Morimoto & Andrea Name Colado Simão

  3. Department of Clinical Medicine, Health Sciences Center, University of Londrina, Av. Robert Koch, 60, 86038-440, Londrina, Paraná, Brazil

    Damacio R. Kaimen-Maciel

  4. Laboratory of Inflammatory Mediators, University of West Paraná, UNIOESTE, Campus Francisco Beltrão, Paraná, Brazil

    Carolina Panis

  5. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia

    Michael Maes

  6. Department of Internal Medicine, University of Londrina, Londrina, Paraná, Brazil

    Isaias Dichi

Authors
  1. Sayonara R. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Paula Kallaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edna M. V. Reiche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Damacio R. Kaimen-Maciel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carolina Panis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcell Alysson B. Lozovoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helena K. Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Isaias Dichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andrea Name Colado Simão
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Name Colado Simão.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oliveira, S.R., Kallaur, A.P., Reiche, E.M.V. et al. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis. Mol Neurobiol 54, 2961–2968 (2017). https://doi.org/10.1007/s12035-016-9860-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-016-9860-z

Keywords

Search

Navigation